A phase II study evaluating the efficacy of enzalutamide and the role of ARv7 in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with visceral disease.

Pierangela Sepe,Giuseppe Procopio,Umberto Basso,Orazio Caffo,Vera Cappelletti,Melanie Claps,Ugo De Giorgi,Lucia Fratino,Valentina Guadalupi,Patrizia Miodini,Bruno Perrucci,Alessia Mennitto,Daniele Santini,Francesco Spina,Arianna Ottini,Filippo de Braud,Elena Verzoni

A phase II study evaluating the efficacy of enzalutamide and the role of ARv7 in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with visceral disease.

2021

Pierangela Sepe
Giuseppe Procopio
Umberto Basso
Orazio Caffo
Vera Cappelletti
Melanie Claps
Ugo De Giorgi
Lucia Fratino
Valentina Guadalupi
Patrizia Miodini
Bruno Perrucci
Alessia Mennitto
Daniele Santini
Francesco Spina
Arianna Ottini
Filippo de Braud
Elena Verzoni

5052Background: Enzalutamide is a second-generation androgen receptor inhibitor that showed to prolong survival in different setting of prostate cancer. Visceral metastases, occurring in 10–30% of ...

Keywords:

castration resistant
Internal medicine
Medicine
Phases of clinical research
Oncology
visceral disease
Androgen receptor
Prostate cancer
Enzalutamide

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations